Clinical work-up of adverse drug reactions

Expert Review of Dermatology

Volumn 2, Issue 2, 2007, Pages 217-231

  Wöhrl, Stefan ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

adverse drug event; diagnosis; drug allergy; drug hypersensitivity; drug provocation challenge; drug provocation test; drug re exposure; drug reaction; skin test

Indexed keywords

EID: 35948994010     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.2.217     Document Type: Article

References (150)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356 (9237), 1255–1259 (2000).
2. Rawlins MD, Thompson JW. Mechanisms of adverse drug reactions. In: Textbook of Adverse Drug Reactions. Davies DM (Ed.). Oxford University Press, Oxford, UK 18–45 (1991).
3. Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 356 (9240), 1505–1511 (2000).
4. Hunziker T, Bruppacher R, Kuenzi UP et al. Classification of ADRs: a proposal for harmonization and differentiation based on the experience of the Comprehensive Hospital Drug Monitoring Bern/St. Gallen, 1974–1993. Pharmacoepidemiol. Drug Saf. 11 (2), 159–163 (2002).
5. Johansson SG, Bieber T, Dahl R et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 113 (5), 832–836 (2004).
6. Pichler WJ. Delayed drug hypersensitivity reactions. Ann. Intern. Med. 139 (8), 683–693 (2003).
7. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 8 (1), E20 –E26 (2006).
8. Perry HM Jr, Tan EM, Carmody S, Sakamoto A. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine. J. Lab. Clin. Med. 76 (1), 114–125 (1970).
9. Batchelor JR, Welsh KI, Tinoco RM et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet 1 (8178), 1107–1109 (1980).
10. Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs. Curr. Allergy Asthma Rep. 3 (1), 22–29 (2003).
11. Pirmohamed M, Naisbitt DJ, Gordon F, Park BK. The danger hypothesis: potential role in idiosyncratic drug reactions. Toxicology 181–182, 55–63 (2002).
12. Gruchalla RS, Pirmohamed M. Clinical practice. Antibiotic allergy. N. Engl. J. Med. 354 (6), 601–609 (2006).
13. Uetrecht J. Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J. 7 (4), E914 –E921 (2005).
14. Pirmohamed M, James S, Meakin S et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. Br. Med. J. 329 (7456), 15–19 (2004).
15. Goodin DS. Evidence-based medicine. Int. MS J. 12 (3), 94–95 (2005).
16. Stevenson DD, Szczeklik A. Clinical and pathologic perspectives on aspirin sensitivity and asthma. J. Allergy Clin. Immunol. 118 (4), 773–786 (2006).
17. Kim SH, Park HS. Pathogenesis of nonsteroidal antiinflammatory drug-induced asthma. Curr. Opin. Allergy Clin. Immunol. 6 (1), 17–22 (2006).
18. Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J. Cutan. Pathol. 28 (3), 113–119 (2001).
19. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin. Cutan. Med. Surg. 15 (4), 250–257 (1996).
20. Mitani N, Aihara M, Yamakawa Y et al. Drug-induced hypersensitivity syndrome due to cyanamide associated with multiple reactivation of human herpesviruses. J. Med. Virol. 75 (3), 430–434 (2005).
21. Roujeau JC. The spectrum of Stevens–Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol. 102 (6), 28S –30S (1994).
22. Naisbitt DJ. Drug hypersensitivity reactions in skin: understanding mechanisms and the development of diagnostic and predictive tests. Toxicology 194 (3), 179–196 (2004).
23. Nassif A, Bensussan A, Boumsell L et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114 (5), 1209–1215 (2004).
24. Wöhrl S, Loewe R, Pickl WF, Stingl G, Wagner SN. EMPACT syndrome. J. Dtsch Dermatol. Ges. 3 (1), 39–43 (2005).
25. Sanderson JP, Naisbitt DJ, Park BK. Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J. 8 (1), E55 –E64 (2006).
26. Naisbitt DJ, Farrell J, Chamberlain PJ et al. Characterization of the T-cell response in a patient with phenindione hypersensitivity. J. Pharmacol. Exp. Ther. 313 (3), 1058–1065 (2005).
27. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol. 2 (4), 301–305 (2002).
28. Gomes E, Cardoso MF, Praca F, Gomes L, Marino E, Demoly P. Self-reported drug allergy in a general adult Portuguese population. Clin. Exp. Allergy 34 (10), 1597–1601 (2004).
29. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279 (15), 1200–1205 (1998).
30. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA 256 (24), 3358–3363 (1986).
31. Sheikh A, Alves B. Hospital admissions for acute anaphylaxis: time trend study. Br. Med. J. 320 (7247), 1441 (2000).
32. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296 (15), 1858–1866 (2006).
33. Macpherson RD, Willcox C, Chow C, Wang A. Anaesthetist’s responses to patients’ self-reported drug allergies. Br. J. Anaesth. 97 (5), 634–639 (2006).
34. MacLaughlin EJ, Saseen JJ, Malone DC. Costs of β-lactam allergies: selection and costs of antibiotics for patients with a reported β-lactam allergy. Arch. Fam. Med. 9 (8), 722–726 (2000).
35. Sade K, Holtzer I, Levo Y, Kivity S. The economic burden of antibiotic treatment of penicillin-allergic patients in internal medicine wards of a general tertiary care hospital. Clin. Exp. Allergy 33 (4), 501–506 (2003).
36. Robinson JL, Hameed T, Carr S. Practical aspects of choosing an antibiotic for patients with a reported allergy to an antibiotic. Clin. Infect. Dis. 35 (1), 26–31 (2002).
37. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 57 (1), 45–51 (2002).
38. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 57 (Suppl. 72), 37–40 (2002).
39. Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 58 (9), 854–863 (2003).
40. Romano A, Blanca M, Torres MJ et al. Diagnosis of nonimmediate reactions to β-lactam antibiotics. Allergy 59 (11), 1153–1160 (2004).
41. Barbaud A, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 45 (6), 321–328 (2001).
42. Executive summary of disease management of drug hypersensitivity: a practice parameter. Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 83 (6 Pt 3), 665–700 (1999).
43. Mertes PM, Laxenaire MC, Lienhart A et al. Reducing the risk of anaphylaxis during anaesthesia: guidelines for clinical practice. J. Investig. Allergol. Clin. Immunol. 15 (2), 91–101 (2005).
44. Wöhrl S, Vigl K, Stingl G. Patients with drug reactions – is it worth testing? Allergy 61 (8), 928–934 (2006).
45. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 54 (9), 999–1003 (1999).
46. Benahmed S, Picot MC, Dumas F, Demoly P. Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions. Arch. Intern. Med. 165 (13), 1500–1505 (2005).
47. Wong BB, Keith PK, Waserman S. Clinical history as a predictor of penicillin skin test outcome. Ann. Allergy Asthma Immunol. 97 (2), 169–174 (2006).
48. Hug K, Yawalkar N, Helbling A, Pichler WJ. Scratch-patch and patch testing in drug allergy – an assessment of specificity. J. Investig. Allergol. Clin. Immunol. 13 (1), 12–19 (2003).
49. Ponvert C. Valeurs diagnostique et prédictive des tests cutanés aux médicaments et substances biologiques. Revue Francaise d’Allergologie et d’Immunologie Clinique 46 (1), 14–28 (2006).
50. Torres MJ, Sanchez-Sabate E, Alvarez J et al. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy 59 (2), 219–224 (2004).
51. Kleinhans M, Linzbach L, Zedlitz S, Kaufmann R, Boehncke WH. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation. Contact Dermatitis 47 (2), 100–102 (2002).
52. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin tests to prove drug hypersensitivity. Br. J. Dermatol. 152 (5), 968–974 (2005).
53. Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J. Allergy Clin. Immunol. 112 (3), 629–630 (2003).
54. Wahlberg J. Patch testing. In: Textbook of Contact Dermatitis. Rycroft RMT, Frosch PJ, Lepoittevin J (Eds). Springer-Verlag, Berlin, Germany 435–468 (2001).
55. Isaksson M, Andersen KE, Brandão FM et al. Patch testing with corticosteroid mixes in Europe. A multicentre study of the EECDRG. Contact Dermatitis 42 (1), 27–35 (2000).
56. Nugent JS, Quinn JM, McGrath CM, Hrncir DE, Boleman WT, Freeman TM. Determination of the incidence of sensitization after penicillin skin testing. Ann. Allergy Asthma Immunol. 90 (4), 398–403 (2003).
57. Blanca M, Mayorga C, Torres MJ et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. Allergy 56 (9), 862–870 (2001).
58. Aberer W, Zidarn M, Kränke B. IgE antibodies to penicillin are indicative for but not conclusive proof of penicillin allergy. Br. J. Dermatol. 154 (6), 1209–1210 (2006).
59. Sanz ML, Gamboa P, de Weck AL. A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int. Arch. Allergy Immunol. 136 (1), 58–72 (2005).
60. Kowalski ML, Ptasinska A, Jedrzejczak M et al. Aspirin-triggered 15-HETE generation in peripheral blood leukocytes is a specific and sensitive Aspirin-Sensitive Patients Identification Test (ASPITest). Allergy 60 (9), 1139–1145 (2005).
61. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 59 (8), 809–820 (2004).
62. Stur K, Karlhofer FM, Stingl G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J. Investig. Dermatol. DOI: 10.1038/sj.jid.5700648 (2006) (Epub ahead of print).
63. Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P. Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann. Intern. Med. 140 (12), 1001–1006 (2004).
64. Blaschke V, Fuchs T. Welche Zukunft hat die stationäre Allergologie? Allergologie 26 (6), 255–258 (2003).
65. Li Wan Po A, Kendall JM. Causality assessment of adverse effects when is re-challenge ethically acceptable? Drug Saf. 24 (11), 793–799 (2001).
66. Atanaskovic-Markovic M, Velickovic TC, Gavrovic-Jankulovic M, Vuckovic O, Nestorovic B. Immediate allergic reactions to cephalosporins and penicillins and their cross-reactivity in children. Pediatr. Allergy Immunol. 16 (4), 341–347 (2005).
67. Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Dermato-Venereologica 85 (6), 491–496 (2005).
68. Laking A, Vieluf D, Kiehn M, Ring J. Bedeutung von oralen Provokationstestungen bei Patienten mit Unverträglichkeitsreaktionen auf Analgetika und NSAR. Allergo J. 8 (8), 347–355 (1999).
69. Torres MJ, Romano A, Mayorga C et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. Allergy 56 (9), 850–856 (2001).
70. Macy E, Mangat R, Burchette RJ. Penicillin skin testing in advance of need: multiyear follow-up in 568 test result-negative subjects exposed to oral penicillins. J. Allergy Clin. Immunol. 111 (5), 1111–1115 (2003).
71. Torres MJ, Blanca M. Importance of skin testing with major and minor determinants of benzylpenicillin in the diagnosis of allergy to βlactams. Statement from the European Network for Drug Allergy concerning AllergoPen withdrawal. Allergy 61 (8), 910–911 (2006).
72. Bousquet PJ, Co-Minh HB, Arnoux B, Daures JP, Demoly P. Importance of mixture of minor determinants and benzylpenicilloyl poly-l-lysine skin testing in the diagnosis of β-lactam allergy. J. Allergy Clin. Immunol. 115 (6), 1314–1316 (2005).
73. Kelkar PS, Li JT. Cephalosporin allergy. N. Engl. J. Med. 345 (11), 804–809 (2001).
74. Romano A, Gueant-Rodriguez RM, Viola M, Pettinato R, Gueant JL. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann. Int. Med. 141 (1), 16–22 (2004).
75. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 115 (4), 1048–1057 (2005).
76. Romano A, Viola M, Gueant-Rodriguez RM, Gaeta F, Pettinato R, Gueant JL. Imipenem in patients with immediate hypersensitivity to penicillins. N. Engl. J. Med. 354 (26), 2835–2837 (2006).
77. Saxon A, Adelman DC, Patel A, Hajdu R, Calandra GB. Imipenem cross-reactivity with penicillin in humans. J. Allergy Clin. Immunol. 82 (2), 213–217 (1988).
78. Renn CN, Straff W, Dorfmüller A, Al-Masaoudi T, Merk HF, Sachs B. Amoxicillin-induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity. Br. J. Dermatol. 147 (6), 1166–1170 (2002).
79. Leung AK, Rafaat M. Eruption associated with amoxicillin in a patient with infectious mononucleosis. Int. J. Dermatol. 42 (7), 553–555 (2003).
80. Gonzalez-Delgado P, Blanes M, Soriano V, Montoro D, Loeda C, Niveiro E. Erythema multiforme to amoxicillin with concurrent infection by Epstein–Barr virus. Allergologia et Immunopathologia 34 (2), 76–78 (2006).
81. Dakdouki GK, Obeid KH, Kanj SS. Azithromycin-induced rash in infectious mononucleosis. Scand. J. Infect. Dis. 34 (12), 939–941 (2002).
82. Ronnau AC, Sachs B, von Schmiedeberg S et al. Cutaneous adverse reaction to ciprofloxacin: demonstration of specific lymphocyte proliferation and cross-reactivity to ofloxacin in vitro. Acta Dermato-Venereologica 77 (4), 285–288 (1997).
83. Manfredi M, Severino M, Testi S et al. Detection of specific IgE to quinolones. J. Allergy Clin. Immunol. 113 (1), 155–160 (2004).
84. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin. Exp. Allergy 36 (1), 59–69 (2006).
85. Notman MJ, Phillips EJ, Knowles SR, Weber EA, Shear NH. Clindamycin skin testing has limited diagnostic potential. Contact Dermatitis 53 (6), 335–338 (2005).
86. Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol. Allergy Clin. North Am. 24 (3), 477–490, VII (2004).
87. Strom BL, Schinnar R, Apter AJ et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N. Engl. J. Med. 349 (17), 1628–1635 (2003).
88. Karila C, Brunet-Langot D, Labbez F et al. Anaphylaxis during anesthesia: results of a 12-year survey at a French pediatric center. Allergy 60 (6), 828–834 (2005).
89. Mertes PM, Laxenaire MC, Alla F. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999–2000. Anesthesiology 99 (3), 536–545 (2003).
90. Jooste EH, Sharma A, Zhang Y, Emala CW. Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. Anesthesiology 103 (6), 1195–1203 (2005).
91. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J. Allergy Clin. Immunol. 111 (5), 913–921 (2003).
92. Cormican LJ, Farooque S, Altmann DR, Lee TH. Improvements in an oral aspirin challenge protocol for the diagnosis of aspirin hypersensitivity. Clin. Exp. Allergy 35 (6), 717–722 (2005).
93. Kasper L, Sladek K, Duplaga M et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58 (10), 1064–1066 (2003).
94. Dieppe PA, Ebrahim S, Martin RM, Juni P. Lessons from the withdrawal of rofecoxib. Br. Med. J. 329 (7471), 867–868 (2004).
95. Woessner KM, Simon RA, Stevenson DD. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease. Ann. Allergy Asthma Immunol. 93 (4), 339–344 (2004).
96. Bannwarth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor. Expert Opin. Investig. Drugs 14 (4), 521–533 (2005).
97. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann. Allergy Asthma Immunol. 95 (2), 154–158 (2005).
98. Weber-Mani U, Reimers A, Pichler WJ, Müller U. Celecoxib (Celebrex)-induzierte Anaphylaxie. Allergologie 25 (10), 534–538 (2002).
99. Sainte-Laudy J, Vallon C. Nine cases of suspected IgE-mediated anaphylaxis induced by aspirin. Allergy Clin. Immunol. Int. 14 (5), 220–222 (2002).
100. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 333 (24), 1600–1607 (1995).
101. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS. The risk of Stevens–Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J. Rheumatol. 30 (10), 2234–2240 (2003).
102. Schnuch A, Gefeller O, Uter W. Eine heimtückische und häufige Nebenwirkung: Kontaktallergien durch das Ekzemtherapeutikum Bufexamac. Ergebnisse des IVDK. Dtsch Med. Wochenschr. 130 (50), 2881–2886 (2005).
103. Heine G, Schnuch A, Uter W, Worm M. Type-IV sensitization profile of individuals with atopic eczema: results from the Information Network of Departments of Dermatology (IVDK) and the German Contact Dermatitis Research Group (DKG). Allergy 61 (5), 611–616 (2006).
104. Morcos SK. Acute serious and fatal reactions to contrast media: our current understanding. Br. J. Radiol. 78 (932), 686–693 (2005).
105. Romano A, Gueant-Rodriguez RM, Viola M, Gaeta F, Caruso C, Gueant JL. Cross-reactivity among drugs: clinical problems. Toxicology 209 (2), 169–179 (2005).
106. Dawson P. Adverse reactions to intravascular contrast agents. Br. Med. J. 333 (7570), 663–664 (2006).
107. Lasser EC, Berry CC, Talner LB et al. Pretreatment with corticosteroids to alleviate reactions to intravenous contrast material. N. Engl. J. Med. 317 (14), 845–849 (1987).
108. Morcos SK, Thomsen HS, Webb JA. Prevention of generalized reactions to contrast media: a consensus report and guidelines. Eur. Radiol. 11 (9), 1720–1728 (2001).
109. Tramèr MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. Br. Med. J. 333 (7570), 675 (2006).
110. Nakada T, Akiyama M, Iijima M, Kato A, Maibach HI. Drug eruptions to contrast media in Japan. Clin. Exp. Dermatol. 31 (3), 361–364 (2006).
111. Peterson A, Katzberg RW, Fung MA, Wootton-Gorges SL, Dager W. Acute generalized exanthematous pustulosis as a delayed dermatotoxic reaction to IV-administered nonionic contrast media. Am. J. Roentgenol. 187 (2), W198 –W201 (2006).
112. Li A, Wong CS, Wong MK, Lee CM, Au Yeung MC. Acute adverse reactions to magnetic resonance contrast media-gadolinium chelates. Br. J. Radiol. 79 (941), 368–371 (2006).
113. Dance D, Basti S, Koch DD. Use of preservative-free lidocaine for cataract surgery in a patient allergic to ‘caines’. Am. J. Cataract Refract. Surg. 31 (4), 848–850 (2005).
114. Gall H, Kaufmann R, Kalveram CM. Adverse reactions to local anesthetics: analysis of 197 cases. J. Allergy Clin. Immunol. 97 (4), 933–937 (1996).
115. Rood JP. Adverse reaction to dental local anaesthetic injection – ‘allergy’ is not the cause. Br. Dent. J. 189 (7), 380–384 (2000).
116. Roesch A, Haegele T, Vogt T, Babilas P, Landthaler M, Szeimies RM. Severe contact urticaria to guar gum included as gelling agent in a local anaesthetic. Contact Dermatitis 52 (6), 307–308 (2005).
117. Krob HA, Fleischer AB Jr, D’Agostino R Jr, Haverstock CL, Feldman S. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T.R.U.E. test data. J. Am. Acad. Dermatol. 51 (3), 349–353 (2004).
118. Romano A, Pettinato R, Andriolo M et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr. Pharmaceut. Des. 12 (26), 3373–3381 (2006).
119. Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 6 (2), 33–37 (2006).
120. Tsopelas C, Sutton R. Why certain dyes are useful for localizing the sentinel lymph node. J. Nucl. Med. 43 (10), 1377–1382 (2002).
121. Montgomery LL, Thorne AC, Van Zee KJ et al. Isosulfan blue dye reactions during sentinel lymph node mapping for breast cancer. Anesth. Analg. 95 (2), 385–388 (2002).
122. Albo D, Wayne JD, Hunt KK et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am. J. Surg. 182 (4), 393–398 (2001).
123. Cimmino VM, Brown AC, Szocik JF et al. Allergic reactions to isosulfan blue during sentinel node biopsy – a common event. Surgery 130 (3), 439–442 (2001).
124. Wöhrl S, Focke M, Hinterhuber G, Stingl G, Binder M. Near-fatal anaphylaxis to patent blue V. Br. J. Dermatol. 150 (5), 1037–1038 (2004).
125. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume substitutes. Lancet 1 (8009), 466–469 (1977).
126. Batra S. Serious cutaneous adverse reactions to traditional Chinese medicines. Singapore Med. J. 47 (7), 647 (2006).
127. Ventura MT, Viola M, Calogiuri G, Gaeta F, Pesole O, Romano A. Hypersensitivity reactions to complementary and alternative medicine products. Curr. Pharmaceut. Des. 12 (26), 3393–3399 (2006).
128. Lim YL, Thirumoorthy T. Serious cutaneous adverse reactions to traditional Chinese medicines. Singapore Med. J. 46 (12), 714–717 (2005).
129. Pichler WJ. Adverse side-effects to biological agents. Allergy 61 (8), 912–920 (2006).
130. Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn’s disease. Drugs 64 (16), 1767–1777 (2004).
131. Bircher AJ. Symptoms and danger signs in acute drug hypersensitivity. Toxicology 209 (2), 201–207 (2005).
132. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens–Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol. Online J. 8 (1), 5 (2002).
133. Oplatek A, Brown K, Sen S, Halerz M, Supple K, Gamelli RL. Long-term follow-up of patients treated for toxic epidermal necrolysis. J. Burn Care Res. 27 (1), 26–33 (2006).
134. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J. Investig. Dermatol. 115 (2), 149–153 (2000).
135. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens–Johnson syndrome: our current understanding. Int. Immunopharmacol. 6 (4), 543–549 (2006).
136. Faye O, Roujeau JC. Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 65 (15), 2085–2090 (2005).
137. Hashim N, Bandara D, Tan E, Ilchyshyn A. Early cyclosporine treatment of incipient toxic epidermal necrolysis induced by concomitant use of lamotrigine and sodium valproate. Acta Dermato-Venereologica 84 (1), 90–91 (2004).
138. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment. J. Allergy Clin. Immunol. 116 (4), 923–924 (2005).
139. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol. 153 (2), 241–253 (2005).
140. Bonifazi F, Jutel M, Bilò BM, Birnbaum J, Müller U. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 60 (12), 1459–1470 (2005).
141. Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D. Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J. Clin. Invest. 83 (5), 1551–1555 (1989).
142. Ludolph-Hauser D, Ruëff F, Sommerhoff CP, Przybilla B. Tryptase, ein Marker für die Aktivierung und Lokalisation von Mastzellen. Hautarzt 50 (8), 556–561 (1999).
143. Komericki P, Arbab E, Grims R, Kränke B, Aberer W. Tryptase as severity marker in drug provocation tests. Int. Arch. Allergy Immunol. 140 (2), 164–169 (2006).
144. Rodríguez-Bada JL, Montañez MI, Torres MJ et al. Skin testing for immediate hypersensitivity to βlactams: comparison between two commercial kits. Allergy 61 (8), 947–951 (2006).
145. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost–effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14 (6), 335–342 (2004).
146. Chung WH, Hung SI, Hong HS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428 (6982), 486 (2004).
147. Lonjou C, Thomas L, Borot N et al. A marker for Stevens–Johnson syndrome…: ethnicity matters. Pharmacogenomics J. 6 (4), 265–268 (2006).
148. Demoly P. Allergie et intolérance (pseudo-allergie) aux médicaments. Définitions. In: Allergie aux Médicaments. Tests Immuno-biologiques. Nicolas J-F, Thivolet J (Eds). Éditions John Libbey Eurotext, Montrouge, France 47–52 (2006).
149. Green GR, Honsinger RW. Introduction. In: Handbook of Drug Allergy. Honsinger RW, Green GR (Eds). Lippincott Williams & Wilkins, PA, USA 17–26 (2004).
150. Vervloet D, Durham S. Adverse reactions to drugs. Br. Med. J. 316 (7143), 1511–1514 (1998).